Abstract:Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) is an attractive therapeutic strategy for targeting cancer metabolism. So far, many potent NAMPT inhibitors have been developed and shown to bind to two unique tunnel-shaped cavities existing adjacent to each active site of a NAMPT homodimer. However, cytotoxicities and resistances to NAMPT inhibitors have become apparent. Therefore, there remains an urgent need to develop effective and safe NAMPT inhibitors. Thus, we designed and synthesized two close structural analogues of NAMPT inhibitors, azaindole–piperidine (3a)- and azaindole–piperazine (3b)-motif compounds, which were modified from the well-known NAMPT inhibitor FK866 (1). Notably, 3a displayed considerably stronger enzyme inhibitory activity and cellular potency than did 3b and 1. The main reason for this phenomenon was revealed to be due to apparent electronic repulsion between the replaced nitrogen atom (N1) of piperazine in 3b and the Nδ atom of His191 in NAMPT by our in silico binding mode analyses. Indeed, 3b had a lower binding affinity score than did 3a and 1, although these inhibitors took similar stable chair conformations in the tunnel region. Taken together, these observations indicate that the electrostatic enthalpy potential rather than entropy effects inside the tunnel cavity has a significant impact on the different binding affinity of 3a from that of 3b in the disparate enzymatic and cellular potencies. Thus, it is better to avoid or minimize interactions with His191 in designing further effective NAMPT inhibitors.

Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening

Data from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma

Discovery and Characterization of Novel Small-Molecule Inhibitors Targeting Nicotinamide Phosphoribosyltransferase

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

Discovery of Novel Inhibitors and Fluorescent Probe Targeting Nampt

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Discovery of Trans-3-(pyridin-3-yl)acrylamide-derived Sulfamides As Potent Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors for the Potential Treatment of Cancer

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

Nicotinamide Phosphoribosyltransferase Inhibitors in Cancer Therapy:An Advance

Structural Basis for Resistance to Diverse Classes of Nampt Inhibitors

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

A Fluorometric Assay for High-Throughput Screening Targeting Nicotinamide Phosphoribosyltransferase

Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase

SAR and Characterization of Non-Substrate Isoindoline Urea Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT)

Identification of Benzothiophene Amides As Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase.

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery